Skip to main content

Table 3 Multivariate Cox-Proportional Hazard analysis of factors associated with TTP and OS

From: Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

 

TTP

OS

Variable

HR

95% C.I.

P

HR

95% C.I.

P

Type of treatment

      

   Vinorelbine

1.0

  

1.0

  

   Docetaxel

0.765

0.538-1.087

0.14

0.474

0.303-0.742

< 0.01

DFI

      

   ≥ 21 months

1.0

  

1.0

  

   < 21 months

1.546

1.092-2.189

0.01

1.945

1.249-3.029

< 0.01

Liver involvement

      

   No

1.0

  

1.0

  

   Yes

1.568

1.1084-2.268

0.02

1.925

1.186-3.125

< 0.01

Number of involved sites

      

   1

1.0

 

0.01

   

   2

1.652

1.071-2.548

0.023

1.568

0.901-2.626

0.12

   ≥ 3

1.999

1.281-3.119

< 0.01

2.004

1.172-3.427

0.01

  1. TTP, time to progression: OS, overall survival: C.I., confidence interval